Blood clotting accelerant is a medication used in conjunction with other medicines to accelerate the process of thrombosis and therefore decrease the duration of chest pain and other related symptoms such as nausea, vomiting, and fever. This product is believed to work by increasing the vascular permeability in the area around the heart and therefore reducing the risk of hemorrhage and consequent loss of blood. The blood clots are broken down by the body into smaller fragments and are then transported to the gastrointestinal tract, lungs, and kidneys, where they clear out.
Blood clotting accelerant can be used to treat: trauma/traumatic brain injury (tbi); rheumatic body injury; orthopedic-related injuries; head and neck injuries; and intracranial hypertension. It can also be used as blood clotting accelerant to reduce the duration of headache and pain. It has been formulated to improve the ability of the body to coagulate and recover from sudden internal or external pressure. Coagulation refers to the process by which the blood clots form and break down on contact with an agent. Blood coagulation is an essential mechanism that prevent bleeding, but blood clotting can also form and break down on contact with an agent, resulting in bleeding.
Market Dynamics
Increasing prevalence of pulmonary embolism is expected to propel growth of the global blood clotting accelerant market. For instance, according to the study, ‘Prevalence of Pulmonary Embolism in Patients With Syncope’, published in Journal of the American College of Cardiology, in August 2019, the incidence of new pulmonary embolisms or cardiovascular death during 2-year follow-up was 0.9%. In the subgroup of patients hospitalized (47%), pulmonary embolism was detected at presentation in 15 patients.
Increasing geriatric population is expected to offer lucrative growth opportunities for players in the global blood clotting accelerant market. For instance, according to the U.S. Census Bureau, the U.S. geriatric population is expected to reach 77 million by 2034.
Emergence of Covid-19 is expected to hinder growth of the global blood clotting accelerant market. For instance, globally, as of 6:51pm CET, 3 January 2021, there have been 83,322,449 confirmed cases of COVID-19, including 1,831,412 deaths, reported to the World Health Organization.
Among regions. Europe is expected to witness significant growth in the global blood clotting accelerant market, owing to high prevalence of venous thromboembolism in the region. For instance, according to NHS Scotland, 75,846 people were admitted to hospital for venous thromboembolism in Scotland from 2008 to 2017.
Competitive Analysis
Major players operating in global blood clotting accelerant market include, Baxter International Inc., PeproTech Inc., Kedrion SpA, Octapharma AG, Novo Nordisk A/S, Sekisui Chemical CO. LTD, CSL Limited, Greiner Bio-One AG, Grifols International SA, and ACROBiosystems.
December 2020: Kedrion SpA, through its Turkish subsidiary Kedrion Betaphar, announced to support the XVII International Congress on Hemophilia organized in Turkey by the country's two leading scientific companies in this therapeutic area.
In-depth Report on Blood Clotting Accelerant Market by Coherent Market Insights:
https://www.coherentmarketinsights.com/ongoing-insight/blood-clotting-accelerant-market-4245
No comments:
Post a Comment